Press Room


    Press Release - July 30, 2008

    Appointment of New Officers

    London, Ontario - July 30, 2008 - Sernova Corp. (TSX-V: SVA)

    Sernova is pleased to announce that Craig Gauld has been appointed as Executive Vice President. Mr. Gauld holds science and law degrees from the University of Western Ontario, and brings over 20 years experience in management, law, finance and administration in the international biotechnology and technology sectors. Mr. Gauld will be replacing current Executive Vice President Phil Morehouse who has resigned effective May 15, 2008 to pursue private business opportunities.

    Sernova is also pleased to announce the appointment of William G. Smethurst as Chief Financial Officer. Mr. Smethurst is a Chartered Accountant with over 25 years experience, starting at Coopers & Lybrand and progressing into senior management positions in the finance, leasing, energy and biotechnology sectors. His expertise includes finance, operations and business development in the private and public sectors. Mr. Smethurst is replacing Patrick Groening who resigned as CFO as of June 30, 2008.

    Justin Leushner, President of Sernova, said: "These two appointments have allowed us to consolidate the management of the company in London, Ontario where our research laboratories are located. Craig and Bill bring many years of international biotechnology experience which will be important as we advance to clinical trials of our lead Sertolin product for diabetes."

    About Sernova

    Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

    For further information contact: Tel: (519) 858-5126



    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News